N-acetylcysteine and Vitamin C oral antioxidant therapy for teprotumumab-related hearing dysfunction: case series and review of literature

We report three cases of successful treatment of teprotumumab-related hearing dysfunction with N-acetylcysteine (NAC) and ascorbic acid (Vitamin C). To investigate NACs effectiveness in the treatment of other types of auditory symptoms through a review of available literature. Three patients with thyroid eye disease (TED) developed symptoms of ear fullness and hearing loss during infusions of teprotumumab. Audiogram revealed above-normal pure tone average hearing threshold frequencies. They were treated with once-daily oral administration of 600 mg N-acetyl cysteine and 500 mg ascorbic acid (Vitamin C). All patients experienced nearly complete resolution of their ear symptoms prior to completing their teprotumumab therapy. They continued to remain symptom-free throughout the remaining teprotumumab infusions and onwards. This study showcases that antioxidant therapy with N-acetylcysteine and Vitamin C appears to be a promising, safe, and inexpensive potential treatment option for teprotumumab-related hearing dysfunction in our patient group.

Authors

Institutions

Publication Details

Journal
Orbit
Published
2026-02-17
DOI
https://doi.org/10.1080/01676830.2025.2608253
Citations
1
Primary Topic
Vestibular and auditory disorders
Type
article
Field-Weighted Citation Impact
30.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

N-acetylcysteine and Vitamin C oral antioxidant therapy for teprotumumab-related hearing dysfunction: case series and review of literature

Elijah Gregory, Ilya M. Leyngold, Eric P. Wilkinson
1 citations
Orbit
Vestibular and auditory disorders
30.63
article

N-acetylcysteine and Vitamin C oral antioxidant therapy for teprotumumab-related hearing dysfunction: case series and review of literature

Elijah Gregory, Ilya M. Leyngold, Eric P. Wilkinson
article en
1 citations

Abstract

We report three cases of successful treatment of teprotumumab-related hearing dysfunction with N-acetylcysteine (NAC) and ascorbic acid (Vitamin C). To investigate NACs effectiveness in the treatment of other types of auditory symptoms through a review of available literature. Three patients with thyroid eye disease (TED) developed symptoms of ear fullness and hearing loss during infusions of teprotumumab. Audiogram revealed above-normal pure tone average hearing threshold frequencies. They were treated with once-daily oral administration of 600 mg N-acetyl cysteine and 500 mg ascorbic acid (Vitamin C). All patients experienced nearly complete resolution of their ear symptoms prior to completing their teprotumumab therapy. They continued to remain symptom-free throughout the remaining teprotumumab infusions and onwards. This study showcases that antioxidant therapy with N-acetylcysteine and Vitamin C appears to be a promising, safe, and inexpensive potential treatment option for teprotumumab-related hearing dysfunction in our patient group.

OrbitVol. 45(2)
University of Washington (US), Eastern Idaho Technical College (US), Plastic Surgery Hospital (CN)
Good health and well-being
Openalex Percentile: Top 1%
Vestibular and auditory disorders
30.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

N-acetylcysteine and Vitamin C oral antioxidant therapy for teprotumumab-related hearing dysfunction: case series and review of literature — Elijah Gregory, Ilya M. Leyngold, et al. · Orbit (2026) | TGRS Research Map | TGRS